Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : OVERSEAS REGULATORY ANNOUNCEMENT (H SHARES)

06/18/2021 | 05:45am EDT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥(集 團)股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the "Announcement in Relation to the Approval for Clinical Trial regarding Investigational New Drug of a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

18 June 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non- executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

  • for identification purposes only

Stock code: 600196

Stock abbreviation: Fosun Pharma Announcement No.: Lin 2021-093

Bond code: 143020

Bond abbreviation: 17 Fosun 01

Bond code: 143422

Bond abbreviation: 18 Fosun 02

Bond code: 155067

Bond abbreviation: 18 Fosun 03

Bond code: 155068

Bond abbreviation: 18 Fosun 01

Bond code: 175708

Bond abbreviation: 21 Fosun 01

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Approval for

Clinical Trial regarding Investigational New Drug of

a Subsidiary

The board of directors of the Company and all members of the Board warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Fochon Pharmaceuticals, Ltd.* ("Fochon Pharmaceutical"), a controlling subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") has recently received the approval from the National Medical Products Administration of consent to commence clinical trial of FCN-098 capsules (the "Investigational New Drug") for the treatment of advanced malignant tumors. Fochon Pharmaceutical intends to conduct Phase I clinical trial of the Investigational New Drug in the PRC (excluding Hong Kong and Macau SAR and Taiwan Region, hereinafter the same) in due course as and when the conditions permitted.

II. Research Progress of the Investigational New Drug

The Investigational New Drug is a second-generation TRK small molecule inhibitor

1

independently developed by the Group (i.e. the Company and its controlling subsidiaries/units, hereinafter the same), and is intended to be used for the treatment of patients with advanced solid tumors with NTRK alterations. As at the date of this announcement, there is no second-generation TRK small molecule inhibitor has been approved for marketing worldwide.

As at May 2021, the Group has cumulatively invested in the R&D of the Investigational New Drug in an aggregate amount of approximately RMB17.16 million (unaudited) at this stage.

III. Risk Warning

As required by the relevant laws and regulations in the PRC, the Investigational New Drug is subject to undergo a series of clinical studies in the PRC and approval from the competent national drug review departments before it comes onto the market. There are certain risks in the R&D of the new drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and marketing of the new drug is a long-term task involving various uncertainties. Investors should be aware of the investment risks.

Announcement is hereby given.

The Board of Directors of

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

18 June 2021

2

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 18 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 June 2021 09:44:05 UTC.


ę Publicnow 2021
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
07/19Sisram Medical Seeks $80 Million in Private Placement; Shares Fall 6%
MT
07/19SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement entering into the placing..
PU
07/19SHANGHAI FOSUN PHARMACEUTICAL (GROUP : Ex-dividend day for final dividend
FA
07/14SINOVAC BIOTECH : Fosun-BioNTech COVID-19 vaccine completes China regulator revi..
RE
07/14MARKET CHATTER : BioNTech's COVID-19 Vaccine Advances to Administration Review i..
MT
07/14SHANGHAI FOSUN PHARMACEUTICAL : Poll results of the resolution proposed at the 2..
PU
07/13Hong Kong says no personal data shared in vaccine deal with Fosun
RE
07/13Sisram Medical Limited completed the acquisition of Shanghai Foshion Medical ..
CI
07/12Politics, health collided in Taiwan's tortured BioNTech vaccine talks
RE
07/11SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma to Sell BioNTech Vaccines to Taiwan..
MT
More news
Financials
Sales 2021 39 915 M 6 139 M 6 139 M
Net income 2021 4 358 M 670 M 670 M
Net Debt 2021 15 917 M 2 448 M 2 448 M
P/E ratio 2021 40,7x
Yield 2021 0,75%
Capitalization 165 B 25 418 M 25 345 M
EV / Sales 2021 4,53x
EV / Sales 2022 4,06x
Nbr of Employees 32 258
Free-Float 58,8%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 68,80 CNY
Average target price 61,26 CNY
Spread / Average Target -11,0%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman